Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Areas of Insight

March 25th, 2022

March 25th, 2022

March 25th, 2022

March 25th, 2022